Adaptimmune Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy ADAP

*Your capital is at risk

$0.0549

+0 (+0%)

At Close: Feb 20, 2026

Adaptimmune Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -95.95. In total, the insiders bought 72.83M and sold 168.16M ADAP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-95.95
● Buy	72.83M shares
● Sell	168.16M shares
48% Buy Activity Strong Positive Correlation
Sell Signal High Confidence Feb 17, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -95.95. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 10, 2025 Buy	Common Stock J-Other	Hill Christopher James Officer	Officer	0 Value: $0
Sep 10, 2025 Buy	Common Stock J-Other	Hill Christopher James Officer	Officer	0 Value: $0
Sep 02, 2025 Sell	Ordinary Shares with a nominal value of GBP0.001 per share S-Sale	Wood Gavin Chief Financial Officer	C-Suite Officer	96 000 Value: $950
Sep 02, 2025 Sell	Ordinary Shares with a nominal value of GBP0.001 per share S-Sale	Wood Gavin Chief Financial Officer	C-Suite Officer	96 000 Value: $950
Aug 28, 2025 Sell	Ordinary Shares with a nominal value of GBP0.001 per share S-Sale	Bertrand William C Jr Chief Operating Officer	C-Suite Officer	207 000 Value: $2K
Aug 28, 2025 Sell	Ordinary Shares with a nominal value of GBP0.001 per share S-Sale	Bertrand William C Jr Chief Operating Officer	C-Suite Officer	207 000 Value: $2K
Aug 18, 2025 Sell	Ordinary Shares with a nominal value of 0.001 GBP per share S-Sale	Behbahani Ali Director	Director	14 671 794 Value: $176.1K
Aug 18, 2025 Sell	Ordinary Shares with a nominal value of 0.001 GBP per share S-Sale	Behbahani Ali Director	Director	14 671 794 Value: $176.1K
Aug 15, 2025 Sell	Ordinary Shares with a nominal value of 0.001 GBP per share S-Sale	Behbahani Ali Director	Director	4 828 206 Value: $53.1K
Aug 15, 2025 Sell	Ordinary Shares with a nominal value of 0.001 GBP per share S-Sale	Behbahani Ali Director	Director	4 828 206 Value: $53.1K
Jul 30, 2025 Sell	Ordinary Shares S-Sale	Ecor1 Capital, Llc 10 Percent Owner	10% Owner	27 433 338 Value: $2.80M
Jul 30, 2025 Sell	Ordinary Shares S-Sale	Ecor1 Capital, Llc 10 Percent Owner	10% Owner	27 433 338 Value: $2.80M
Jul 29, 2025 Sell	Ordinary Shares S-Sale	Ecor1 Capital, Llc 10 Percent Owner	10% Owner	2 687 460 Value: $272.0K
Jul 29, 2025 Sell	Ordinary Shares S-Sale	Ecor1 Capital, Llc 10 Percent Owner	10% Owner	2 687 460 Value: $272.0K
Jul 28, 2025 Sell	Ordinary Shares S-Sale	Ecor1 Capital, Llc 10 Percent Owner	10% Owner	33 931 740 Value: $3.82M
Jul 28, 2025 Sell	Ordinary Shares S-Sale	Ecor1 Capital, Llc 10 Percent Owner	10% Owner	33 931 740 Value: $3.82M
Feb 20, 2025 Buy	Option to purchase Ordinary Shares A-Award	Bertrand William C Jr Chief Operating Officer	C-Suite Officer	1 612 032 Value: $161.2K
Feb 20, 2025 Buy	Option to purchase Ordinary Shares A-Award	Bertrand William C Jr Chief Operating Officer	C-Suite Officer	1 074 696 Value: $1K
Feb 20, 2025 Buy	Option to purchase Ordinary Shares A-Award	Brewer Joanna Elizabeth Chief Scientific Officer	Officer	1 612 032 Value: $161.2K
Feb 20, 2025 Buy	Option to purchase Ordinary Shares A-Award	Brewer Joanna Elizabeth Chief Scientific Officer	Officer	1 074 696 Value: $1K
Feb 20, 2025 Buy	Option to purchase Ordinary Shares A-Award	Lunger John Chief Patient Supply Officer	Officer	1 612 032 Value: $161.2K
Feb 20, 2025 Buy	Option to purchase Ordinary Shares A-Award	Lunger John Chief Patient Supply Officer	Officer	1 074 696 Value: $1K
Feb 20, 2025 Buy	Option to purchase Ordinary Shares A-Award	Piccina Cintia Chief Commercial Officer	Officer	1 612 032 Value: $161.2K
Feb 20, 2025 Buy	Option to purchase Ordinary Shares A-Award	Piccina Cintia Chief Commercial Officer	Officer	1 074 696 Value: $1K
Feb 20, 2025 Buy	Option to purchase Ordinary Shares A-Award	Norry Elliot Chief Medical Officer	Officer	1 612 032 Value: $161.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ADAPTIMMUNE THERAPEUTICS PLC

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa...

Read Full Profile Here